TMIE

Summary

TMIE (transmembrane inner ear, HGNC:30800) is a protein-coding gene on chromosome 3p21.31, encoding Transmembrane inner ear expressed protein (Q8NEW7). Auxiliary subunit of the mechanotransducer (MET) non-specific cation channel complex located at the tips of stereocilia of cochlear hair cells and that mediates sensory transduction in the auditory system.

This gene encodes a transmembrane inner ear protein. Studies in mouse suggest that this gene is required for normal postnatal maturation of sensory hair cells in the cochlea, including correct development of stereocilia bundles. This gene is one of multiple genes responsible for recessive non-syndromic deafness (DFNB), also known as autosomal recessive nonsyndromic hearing loss (ARNSHL), the most common form of congenitally acquired inherited hearing impairment.

Source: NCBI Gene 259236 — RefSeq curated summary.

At a glance

• Gene–disease (curated): nonsyndromic genetic hearing loss (Definitive, ClinGen) — +2 more curated relationships
• Clinical variants (ClinVar): 144 total — 8 pathogenic, 6 likely-pathogenic
• Phenotypes (HPO): 3
• MANE Select transcript: NM_147196

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:30800
Approved symbol	TMIE
Name	transmembrane inner ear
Location	3p21.31
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000181585
Ensembl biotype	protein_coding
OMIM	607237
Entrez	259236

Gene structure

Transcript identifiers

Ensembl transcripts: 3 — 3 protein_coding

ENST00000643606, ENST00000644830, ENST00000651652

RefSeq mRNA: 3 — MANE Select: NM_147196 NM_001370524, NM_001370525, NM_147196

CCDS: CCDS43081, CCDS93259

Canonical transcript exons

ENST00000643606 — 4 exons

Exon	Start	End
ENSE00001268869	46709126	46709275
ENSE00001268877	46705790	46705907
ENSE00001301153	46709579	46710886
ENSE00003825686	46701392	46701580

Expression profiles

Bgee: expression breadth ubiquitous, 167 present calls, max score 82.96.

FANTOM5 (CAGE): breadth broad, TPM avg 0.5248 / max 44.2193, expressed in 186 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
36495	0.2806	130
36496	0.2442	40

Top tissues by expression

225 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	82.96	gold quality
hypothalamus	UBERON:0001898	81.40	gold quality
anterior cingulate cortex	UBERON:0009835	79.12	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	78.99	silver quality
pituitary gland	UBERON:0000007	78.86	gold quality
adenohypophysis	UBERON:0002196	78.51	gold quality
right frontal lobe	UBERON:0002810	78.16	gold quality
amygdala	UBERON:0001876	77.26	gold quality
Brodmann (1909) area 9	UBERON:0013540	76.97	gold quality
prefrontal cortex	UBERON:0000451	76.79	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	75.67	gold quality
neocortex	UBERON:0001950	75.60	gold quality
frontal cortex	UBERON:0001870	75.40	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	75.34	gold quality
middle temporal gyrus	UBERON:0002771	74.93	gold quality
cerebral cortex	UBERON:0000956	74.54	gold quality
spinal cord	UBERON:0002240	74.50	gold quality
substantia nigra	UBERON:0002038	74.18	gold quality
Ammon’s horn	UBERON:0001954	73.78	gold quality
temporal lobe	UBERON:0001871	73.65	gold quality
epithelium of nasopharynx	UBERON:0001951	73.35	gold quality
midbrain	UBERON:0001891	73.15	gold quality
forebrain	UBERON:0001890	73.06	gold quality
brain	UBERON:0000955	72.27	gold quality
endothelial cell	CL:0000115	70.66	silver quality
ventricular zone	UBERON:0003053	69.94	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	69.63	gold quality
sperm	CL:0000019	69.35	gold quality
lower esophagus mucosa	UBERON:0035834	69.28	gold quality
cerebellar vermis	UBERON:0004720	69.22	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	1.11

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): NR1H4

miRNA regulators (miRDB)

26 targeting TMIE, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4650-5P	99.98	64.69	999
HSA-MIR-6756-5P	99.82	67.97	2466
HSA-MIR-10393-3P	99.72	66.56	961
HSA-MIR-6801-5P	99.72	66.50	981
HSA-MIR-6766-5P	99.68	67.70	2325
HSA-MIR-6892-3P	99.68	66.40	1178
HSA-MIR-3175	99.65	66.30	2031
HSA-MIR-1205	99.65	66.76	1826
HSA-MIR-103A-2-5P	99.39	67.72	1577
HSA-MIR-103A-1-5P	99.39	67.78	1545
HSA-MIR-361-3P	99.19	66.45	1381
HSA-MIR-6815-3P	99.13	68.98	1530
HSA-MIR-760	98.81	66.65	1392
HSA-MIR-4755-3P	98.77	65.59	1915
HSA-MIR-210-5P	98.57	64.37	832
HSA-MIR-6819-5P	97.96	66.59	1071
HSA-MIR-6810-3P	97.96	64.57	1023
HSA-MIR-3664-3P	97.85	67.62	1452
HSA-MIR-6737-5P	97.75	66.54	1044
HSA-MIR-6812-5P	97.56	65.39	1059
HSA-MIR-3157-5P	97.41	67.61	998
HSA-MIR-4288	97.11	67.23	1636
HSA-MIR-3116	97.07	65.78	1324
HSA-MIR-6773-5P	97.04	64.30	595
HSA-MIR-4727-3P	96.75	64.97	415
HSA-MIR-6508-3P	96.73	65.48	576

Literature-anchored findings (GeneRIF, showing 7)

• genetic mapping data support human TMIE as the gene affected at DFNB6, a non-syndromic hearing loss locus (PMID:12140191)
• identification of 5 different homozygous recessive mutations in a novel gene, TMIE= transmembrane inner ear expressed gene, in affected members of consanguineous families segregating severe-to-profound prelingual deafness, consistent with linkage to DFNB6 (PMID:12145746)
• The circling mouse is a potential animal model for DFNB6 deafness in humans. (PMID:14727813)
• p.R84W could be a common mutation in other Middle Eastern populations and should be included in mutation screening offered to individuals with autosomal recessive non-syndromic sensorineural hearing loss (ARNSSNHL) (PMID:19438934)
• We suggest that a missense variant and one promoter variant is de novo and may be a risk factor for the development of hearing loss in Taiwanese (PMID:20206386)
• Description of the spectrum of mutations in TMIE in 374 families with autosomal recessive, non-syndromic hearing loss from India. (PMID:24416283)
• Analysis of TMIE gene mutations including the first large deletion of exon 1 with autosomal recessive non-syndromic deafness. (PMID:35710363)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Tmie	ENSMUSG00000049555
rattus_norvegicus	Tmie	ENSRNOG00000027799

Protein

Protein identifiers

Transmembrane inner ear expressed protein — Q8NEW7 (reviewed: Q8NEW7)

All UniProt accessions (3): A0A2R8YDZ8, A0A494C1A3, Q8NEW7

UniProt curated annotations — full annotation on UniProt →

Function. Auxiliary subunit of the mechanotransducer (MET) non-specific cation channel complex located at the tips of stereocilia of cochlear hair cells and that mediates sensory transduction in the auditory system. The MET complex is composed of two dimeric pore-forming ion-conducting transmembrane TMC (TMC1 or TMC2) subunits, and aided by several auxiliary proteins including LHFPL5, TMIE, CIB2/3 and TOMT, and the tip-link PCDH15. May contribute to the formation of the pore.

Subunit / interactions. Forms the MET channel composed of TMC (TMC1 or TMC2), TMIE, TOMT, CIB (CIB2 or CIB3), LHPL5 and PCDH15.

Subcellular location. Membrane.

Tissue specificity. Expressed in many tissues.

Disease relevance. Deafness, autosomal recessive, 6 (DFNB6) [MIM:600971] A form of non-syndromic sensorineural hearing loss. Sensorineural deafness results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information. The disease is caused by variants affecting the gene represented in this entry.

RefSeq proteins (3): NP_001357453, NP_001357454, NP_671729* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR032006	TMIE	Family

Pfam: PF16038

UniProt features (10 total): sequence variant 3, topological domain 2, signal peptide 1, chain 1, transmembrane region 1, region of interest 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8NEW7-F1	63.41	0.07

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

ID	Pathway
R-HSA-9662360	Sensory processing of sound by inner hair cells of the cochlea
R-HSA-9662361	Sensory processing of sound by outer hair cells of the cochlea

MSigDB gene sets: 100 (showing top): GOBP_SENSORY_PERCEPTION_OF_MECHANICAL_STIMULUS, GOBP_ANIMAL_ORGAN_MORPHOGENESIS, GOBP_EAR_DEVELOPMENT, GOBP_EMBRYONIC_ORGAN_MORPHOGENESIS, GOBP_EAR_MORPHOGENESIS, RYTTCCTG_ETS2_B, GOBP_SENSORY_PERCEPTION, RFX1_02, GOBP_EMBRYO_DEVELOPMENT, GOBP_SENSORY_ORGAN_DEVELOPMENT, GOBP_SENSORY_ORGAN_MORPHOGENESIS, GOBP_EMBRYONIC_ORGAN_DEVELOPMENT, GOBP_INNER_EAR_MORPHOGENESIS, GAVIN_FOXP3_TARGETS_CLUSTER_P4, GAVIN_IL2_RESPONSIVE_FOXP3_TARGETS_DN

GO Biological Process (2): sensory perception of sound (GO:0007605), inner ear morphogenesis (GO:0042472)

GO Molecular Function (0):

GO Cellular Component (1): membrane (GO:0016020)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Sensory processing of sound	2

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
sensory perception of mechanical stimulus	1
ear morphogenesis	1
embryonic morphogenesis	1
inner ear development	1
cellular anatomical structure	1

Protein interactions and networks

STRING

308 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TMIE	LHFPL5	Q8TAF8	984
TMIE	TMC1	Q8TDI8	978
TMIE	GJB2	P29033	896
TMIE	TMC2	Q8TDI7	864
TMIE	PCDH15	Q96QU1	790
TMIE	CIB2	O75838	752
TMIE	TMPRSS3	P57727	731
TMIE	MYO15A	Q9UKN7	673
TMIE	CDH23	Q9H251	665
TMIE	E9PNW1	E9PNW1	645
TMIE	OTOF	Q9HC10	620
TMIE	SLC26A4	O43511	598
TMIE	TRIOBP	Q9H2D6	595
TMIE	GRXCR1	A8MXD5	582
TMIE	TMPRSS4	Q9NRS4	582
TMIE	OTOA	Q7RTW8	582

IntAct

4 interactions, top by confidence:

A	B	Type	Score
P		psi-mi:“MI:0914”(association)	0.350
TMIE	TRIM3	psi-mi:“MI:0914”(association)	0.350

BioGRID (31): TMIE (Two-hybrid), TMIE (Two-hybrid), TMIE (Two-hybrid), TMIE (Two-hybrid), TMIE (Two-hybrid), TMIE (Two-hybrid), TMIE (Two-hybrid), TMIE (Two-hybrid), TMIE (Two-hybrid), TMIE (Two-hybrid), TMIE (Two-hybrid), TMIE (Two-hybrid), TMIE (Two-hybrid), TMIE (Two-hybrid), TMIE (Two-hybrid)

ESM2 similar proteins: D4A6L0, I3LMB3, O00168, O73698, O76095, O77049, O88823, O88824, O97797, P0C851, P54710, P56513, P59645, P59646, Q04645, Q04646, Q04679, Q04680, Q08CB3, Q14802, Q1RMB5, Q1XF11, Q3MHZ5, Q3SZX0, Q3UPR0, Q4R566, Q5RB29, Q5T848, Q61835, Q63113, Q66IQ1, Q6X9T8, Q70RD5, Q810F0, Q86XR5, Q8C419, Q8K467, Q8NEW7, Q8QZT4, Q8R143

Diamond homologs: Q8K467, Q8NEW7

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

144 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	8
Likely pathogenic	6
Uncertain significance	65
Likely benign	22
Benign	20

Top pathogenic / likely-pathogenic (14)

Variant ID	HGVS	Classification
1185676	NM_147196.3(TMIE):c.144_145del (p.Val49fs)	Pathogenic
1342310	NM_001370524.1(TMIE):c.-507_-66-2329del	Pathogenic
2418284	NM_147196.3(TMIE):c.362-2A>G	Pathogenic
3389	NM_147196.3(TMIE):c.122_125del (p.Pro41fs)	Pathogenic
3392	NM_147196.3(TMIE):c.274C>T (p.Arg92Trp)	Pathogenic
3393	NM_147196.3(TMIE):c.94-2_98delinsC	Pathogenic
3394	NM_147196.3(TMIE):c.170G>A (p.Trp57Ter)	Pathogenic
3601927	NM_147196.3(TMIE):c.286C>T (p.Arg96Ter)	Pathogenic
1180704	NM_147196.3(TMIE):c.349G>T (p.Glu117Ter)	Likely pathogenic
3391	NM_147196.3(TMIE):c.250C>T (p.Arg84Trp)	Likely pathogenic
3601928	NM_147196.3(TMIE):c.87_88insT (p.Val30fs)	Likely pathogenic
3780719	NM_147196.3(TMIE):c.361+1G>A	Likely pathogenic
47957	NM_147196.3(TMIE):c.211+3G>C	Likely pathogenic
47958	NM_147196.3(TMIE):c.251G>T (p.Arg84Leu)	Likely pathogenic

SpliceAI

634 predictions. Top by Δscore:

Variant	Effect	Δscore
3:46705788:A:AG	acceptor_gain	1.0000
3:46705789:G:GG	acceptor_gain	1.0000
3:46705789:GCCC:G	acceptor_gain	1.0000
3:46705789:GCCCA:G	acceptor_gain	1.0000
3:46705905:TCA:T	donor_gain	1.0000
3:46705908:G:GG	donor_gain	1.0000
3:46709121:TACAG:T	acceptor_loss	1.0000
3:46709122:A:AG	acceptor_gain	1.0000
3:46709122:ACAGT:A	acceptor_loss	1.0000
3:46709123:C:G	acceptor_gain	1.0000
3:46709123:CAGTC:C	acceptor_loss	1.0000
3:46709124:A:AG	acceptor_gain	1.0000
3:46709125:G:GT	acceptor_gain	1.0000
3:46709125:G:T	acceptor_loss	1.0000
3:46709125:GT:G	acceptor_gain	1.0000
3:46709125:GTC:G	acceptor_gain	1.0000
3:46709125:GTCA:G	acceptor_gain	1.0000
3:46709125:GTCAT:G	acceptor_gain	1.0000
3:46709271:AGGAG:A	donor_gain	1.0000
3:46709272:GGAG:G	donor_gain	1.0000
3:46709272:GGAGG:G	donor_gain	1.0000
3:46709273:G:GT	donor_gain	1.0000
3:46709273:GAG:G	donor_gain	1.0000
3:46709273:GAGGT:G	donor_loss	1.0000
3:46709276:G:GG	donor_gain	1.0000
3:46709276:GTGA:G	donor_loss	1.0000
3:46709277:T:G	donor_loss	1.0000
3:46709574:CACA:C	acceptor_loss	1.0000
3:46709575:ACAG:A	acceptor_loss	1.0000
3:46709576:CAGA:C	acceptor_loss	1.0000

AlphaMissense

1005 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
3:46705865:T:A	W57R	1.000
3:46705865:T:C	W57R	1.000
3:46705867:G:C	W57C	0.999
3:46705867:G:T	W57C	0.999
3:46705878:G:A	G61D	0.999
3:46709137:T:C	C75R	0.999
3:46709138:G:A	C75Y	0.999
3:46709162:C:A	P83Q	0.999
3:46709180:T:G	I89S	0.999
3:46709185:G:C	A91P	0.999
3:46709201:G:C	R96P	0.999
3:46705877:G:C	G61R	0.998
3:46709161:C:A	P83T	0.998
3:46709161:C:T	P83S	0.998
3:46709180:T:A	I89N	0.998
3:46705859:C:A	R55S	0.997
3:46709139:C:G	C75W	0.997
3:46709140:T:C	C76R	0.997
3:46709144:T:A	V77D	0.997
3:46709152:T:C	C80R	0.997
3:46709155:C:A	R81S	0.997
3:46709168:C:T	T85I	0.997
3:46709189:G:C	R92P	0.997
3:46709206:G:C	A98P	0.997
3:46709231:T:C	L106P	0.997
3:46705848:T:C	F51S	0.996
3:46709137:T:A	C75S	0.996
3:46709138:G:C	C75S	0.996
3:46709155:C:G	R81G	0.996
3:46709161:C:G	P83A	0.996

dbSNP variants (sampled 300 via entrez): RS1000033865 (3:46697512 C>G), RS1000130916 (3:46711245 T>C), RS1000156454 (3:46704525 C>A,G,T), RS1000246102 (3:46710850 G>T), RS1000295317 (3:46695061 C>T), RS1000770567 (3:46701622 C>T), RS1000823488 (3:46701433 A>G), RS1001059427 (3:46707750 C>G,T), RS1001286857 (3:46696864 G>A,T), RS1001380427 (3:46703687 A>C), RS1001653865 (3:46709417 T>A,C), RS1001772735 (3:46703071 C>T), RS1001823530 (3:46702834 G>A,T), RS1001837689 (3:46710151 G>T), RS1002127314 (3:46709747 A>C)

Disease associations

OMIM: gene MIM:607237 | disease phenotypes: MIM:600971, MIM:128600, MIM:220290, MIM:607197

GenCC curated gene-disease

Disease	Classification	Inheritance
nonsyndromic genetic hearing loss	Definitive	Autosomal recessive
autosomal recessive nonsyndromic hearing loss 6	Strong	Autosomal recessive
hearing loss, autosomal recessive	Supportive	Autosomal recessive

ClinGen Gene-Disease Validity (1)

Expert-panel classifications — Definitive > Strong > Moderate > Limited > Disputed > Refuted.

Disease	Classification	Inheritance
nonsyndromic genetic hearing loss	Definitive	AR

Mondo (6): autosomal recessive nonsyndromic hearing loss 6 (MONDO:0010965), ear malformation (MONDO:0007500), hearing loss, autosomal recessive (MONDO:0019588), sensorineural hearing loss disorder (MONDO:0020678), hearing loss disorder (MONDO:0005365), nonsyndromic genetic hearing loss (MONDO:0019497)

Orphanet (3): Rare autosomal recessive non-syndromic sensorineural deafness type DFNB (Orphanet:90636), Rare autosomal dominant non-syndromic sensorineural deafness type DFNA (Orphanet:90635), Rare genetic deafness (Orphanet:96210)

HPO phenotypes

3 total (4 of 3 shown, HPO-id order):

HPO	Term
HP:0000007	Autosomal recessive inheritance
HP:0000365	Hearing impairment
HP:0003577	Congenital onset
HP:0000407	Sensorineural hearing impairment

GWAS associations

0 associations (top):

MeSH disease descriptors (4)

Descriptor	Name	Tree numbers
D034381	Hearing Loss	C09.218.458.341; C10.597.751.418.341; C23.888.592.763.393.341
C564609	Deafness, Autosomal Recessive (supp.)
C563418	Deafness, Autosomal Recessive 6 (supp.)
C580334	Nonsyndromic Deafness (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

17 total (human), top 17 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	decreases expression, increases expression	2
bisphenol A	affects methylation	1
butyraldehyde	increases expression	1
benzo(e)pyrene	decreases methylation	1
ferrous chloride	decreases expression	1
2-palmitoylglycerol	increases expression	1
entinostat	increases expression	1
abrine	increases expression	1
Sunitinib	increases expression	1
Benzo(a)pyrene	increases methylation	1
Methapyrilene	decreases methylation	1
Rotenone	decreases expression	1
Valproic Acid	increases expression	1
Cyclosporine	increases expression	1
Aflatoxin B1	decreases methylation	1
Cadmium Chloride	decreases expression	1
Okadaic Acid	increases expression	1

Clinical trials (associated diseases)

299 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00205881	PHASE4	COMPLETED	Bilateral Benefit in Adult Users of the HiRes 90K Bionic Ear System
NCT00331539	PHASE4	UNKNOWN	Relationship Between Auto NRT and Behavioural T & C Levels With the Nucleus Freedom Cochlear Implant
NCT00424307	PHASE4	UNKNOWN	Bilateral Cochlear Implant Benefit in Young Children
NCT00765635	PHASE4	COMPLETED	Chlorobutanol, Potassium Carbonate, and Irrigation in Cerumen Removal
NCT03321006	PHASE4	COMPLETED	Treating Hearing Loss to Improve Mood and Cognition in Older Adults
NCT01655212	PHASE3	TERMINATED	Congenital Cytomegalovirus: Efficacy of Antiviral Treatment in a Randomized Controlled Trial
NCT02005822	PHASE3	COMPLETED	Congenital Cytomegalovirus: Efficacy of Antiviral Treatment
NCT03374514	PHASE3	UNKNOWN	Cochlear Electrical Impedance and the Effect of Topical Dexamethasone on Cochlear Implant Surgery
NCT01499901	PHASE3	WITHDRAWN	Comparison of the Bilateral Sequential and Simultaneous Cochlear Implantation in the Deaf Children
NCT02561091	PHASE3	COMPLETED	AM-111 in the Treatment of Acute Inner Ear Hearing Loss
NCT03331627	PHASE3	COMPLETED	Safety and Efficacy of STR001-IT and STR001-ER in Patients With SSHL
NCT05532657	PHASE3	ACTIVE_NOT_RECRUITING	ACHIEVE Brain Health Follow-Up Study
NCT02497690	PHASE2	COMPLETED	Effectiveness of Therapy Via Telemedicine Following Cochlear Implants
NCT03107871	PHASE2	ACTIVE_NOT_RECRUITING	Randomized Controlled Trial of Valganciclovir for Cytomegalovirus Infected Hearing Impaired Infants
NCT04120116	PHASE2	COMPLETED	FX-322 in Adults With Stable Sensorineural Hearing Loss
NCT05061758	PHASE2	WITHDRAWN	A Trial of LY3056480 in Patients With SNLH
NCT07364747	PHASE2	RECRUITING	Protective Effect of Acetylcysteine Against Cisplatinum-Induced Ototoxicity: A Randomized Controlled Trial
NCT00013455	PHASE2	COMPLETED	Quantifying Auditory Perceptual Learning Following Hearing Aid Fitting
NCT00323427	PHASE2	COMPLETED	Clinical Trial of the Living Well With Hearing Loss Workshop
NCT00552786	PHASE2	COMPLETED	Antioxidation Medication for Noise-induced Hearing Loss
NCT00802425	PHASE2	COMPLETED	Efficacy of AM-111 in Patients With Acute Sensorineural Hearing Loss
NCT01139281	PHASE2	COMPLETED	The Protective Effect of Ginkgo Biloba Extract on Cisplatin-induced Ototoxicity in Humans
NCT01451853	PHASE2	UNKNOWN	SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss
NCT01588925	PHASE2	COMPLETED	Hearing Preservation Using Dexamethasone and Hyaluronic Acid for Cochlear Implantation
NCT01773278	PHASE2	RECRUITING	Cholesterol and Antioxidant Treatment in Patients With Smith-Lemli-Opitz Syndrome (SLOS)
NCT02832128	PHASE2	COMPLETED	Evaluating Possible Improvement in Speech and Hearing Tests After 28 Days of Dosing of the Study Drug AUT00063 Compared to Placebo (QuicKfire)
NCT04915183	PHASE2	RECRUITING	Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer
NCT05258773	PHASE2	COMPLETED	Evaluation of the Presence of SENS-401 in the Perilymph
NCT06340633	PHASE2	RECRUITING	SPI-1005 in Adults Receiving Cochlear Implant
NCT02259595	PHASE1	COMPLETED	Study to Determine the Safety, Tolerability, and Pharmacokinetic Profile of HPN-07 and HPN-07 Plus NAC
NCT00582946	PHASE1	COMPLETED	Wide-Bandwidth Open Canal Hearing Aid For Better Multitalker Speech Understanding
NCT00584155	PHASE1	WITHDRAWN	Protection From Cisplatin Ototoxicity by Lactated Ringers
NCT01206829	PHASE1	UNKNOWN	Hearing Impairment, Cognitive Therapy and Coping
NCT01256229	PHASE1	COMPLETED	Outcomes In Children With Developmental Delay And Deafness
NCT01343394	PHASE1	WITHDRAWN	Safety of Autologous Human Umbilical Cord Blood Mononuclear Fraction to Treat Acquired Hearing Loss in Children
NCT01452607	PHASE1	COMPLETED	Study to Evaluate the Safety and Pharmacokinetics of SPI-1005
NCT04041440	PHASE1	COMPLETED	Speech Recognition Training in Children With Hearing Loss
NCT07218913	PHASE1	RECRUITING	Testing the Addition of Pedmark to Cisplatin Chemotherapy for Reducing Drug-Induced Ear Damage in Men With Stage II-III Metastatic Testicular Germ Cell Tumors
NCT01802190	Not specified	TERMINATED	Prevalence of POU4F3 and SLC17A8 Mutations
NCT06431698	Not specified	UNKNOWN	CORRECTION OF EAR DEFORMITIES IN NEWBORNS BY MODELING, COMPARISON OF TWO PROTOCOLS